Secretin-Stimulation of Bicarbonate Secretion Reduces Biliary Damage and Liver Fibrosis in a Model of Primary Biliary Cholangitis (PBC)

2017 ◽  
Vol 152 (5) ◽  
pp. S1060 ◽  
Author(s):  
Lindsey Kennedy ◽  
Heather L. Francis ◽  
Julie Venter ◽  
Laura Hargrove ◽  
Pietro Invernizzi ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Primary Biliary Cholangitis ◽  
Bicarbonate Secretion ◽  
Secretin Stimulation ◽  
Stimulation Of

scholarly journals Diagnosis and Therapeutic Management of Liver Fibrosis by microRNA

2021 ◽  
Vol 22 (15) ◽  
pp. 8139
Author(s):  
Tomoko Tadokoro ◽  
Asahiro Morishita ◽  
Tsutomu Masaki
Keyword(s):  
Liver Fibrosis ◽  
Viral Infections ◽  
Primary Biliary Cholangitis ◽  
Medical Need ◽  
Key Factor ◽  
Complications Of Cirrhosis ◽  
And Control ◽  
Functional Rnas ◽  
Remarkable Progress ◽  
Made In

Remarkable progress has been made in the treatment and control of hepatitis B and C viral infections. However, fundamental treatments for diseases in which liver fibrosis is a key factor, such as cirrhosis, alcoholic/nonalcoholic steatohepatitis, autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, are still under development and remain an unmet medical need. To solve this problem, it is essential to elucidate the pathogenesis of liver fibrosis in detail from a molecular and cellular perspective and to develop targeted therapeutic agents based on this information. Recently, microRNAs (miRNAs), functional RNAs of 22 nucleotides, have been shown to be involved in the pathogenesis of liver fibrosis. In addition, extracellular vesicles called “exosomes” have been attracting attention, and research is being conducted to establish noninvasive and extremely sensitive biomarkers using miRNAs in exosomes. In this review, we summarize miRNAs directly involved in liver fibrosis, miRNAs associated with diseases leading to liver fibrosis, and miRNAs related to complications of cirrhosis. We will also discuss the efficacy of each miRNA as a biomarker of liver fibrosis and pathology, and its potential application as a therapeutic agent.

Neuronal cGMP kinase I is essential for stimulation of duodenal bicarbonate secretion by luminal acid

2012 ◽  
Vol 26 (4) ◽  
pp. 1745-1754 ◽  
Author(s):  
Anurag Kumar Singh ◽  
Beate Spieβberger ◽  
Wen Zheng ◽  
Fang Xiao ◽  
Robert Lukowski ◽  
...  
Keyword(s):  
Bicarbonate Secretion ◽  
Duodenal Bicarbonate Secretion ◽  
Stimulation Of

557 - Melatonin and Dark Therapy Reduce Biliary Damage, Liver Fibrosis and Angiogenesis in a Murine Model of Early Stage Primary Biliary Cholangitis (PBC)

2018 ◽  
Vol 154 (6) ◽  
pp. S-1096-S-1097
Author(s):  
Lindsey Kennedy ◽  
Nan Wu ◽  
Heather L. Francis ◽  
Julie Venter ◽  
Fanyin Meng ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Murine Model ◽  
Early Stage ◽  
Primary Biliary Cholangitis

scholarly journals Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies

2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Danielle Cristiane Baldo ◽  
Alessandra Dellavance ◽  
Maria Lucia Gomes Ferraz ◽  
Luis Eduardo C. Andrade
Keyword(s):  
Liver Fibrosis ◽  
Rat Kidney ◽  
Surrogate Marker ◽  
Serum Levels ◽  
Autoimmune Response ◽  
Primary Biliary Cholangitis ◽  
Gamma Glutamyl Transferase ◽  
Normal Individuals ◽  
Glutamyl Transferase

Abstract Background Anti-mitochondria autoantibodies (AMA) occur in > 95% primary biliary cholangitis (PBC) patients. Biochemically normal AMA-positive (BN/AMA+) individuals, occasionally noticed by indirect immunofluorescence (IIF) on HEp-2 cells and confirmed in AMA-specific assays, may represent early stages of PBC. The Enhanced Liver Fibrosis (ELF) score is a surrogate marker for liver fibrosis. This prospective study investigated the ELF score in BN/AMA+ individuals and PBC patients, considering autoantibody avidity and serum levels along the years. Methods 327 samples from 35 PBC and 59 BN/AMA+ were prospectively obtained in average 3.83 (range 0.50–7.40) years apart. Samples were tested by IIF on rat-kidney (IIF-AMA), western-blot for AMA (WB-AMA), and ELISA for antibodies against pyruvate-dehydrogenase (PDC-E2), gp210, sp100 and CENP-A/B. Anti-PDC-E2 avidity was determined by 6 M urea-elution ELISA. Alkaline phosphatase (ALP), gamma glutamyl transferase (ɣGT) and ELF score were measured by automated methods. Results Along the follow-up period BN/AMA+ subjects and PBC patients presented significant increase in serum anti-PDC-E2 (mean 10.45% and 8.86% per year; respectively), anti-PDC-E2 avidity (3.02% and 4.94%/year) and ELF score (3.24% and 2.71%/year). IIF-AMA and ɣGT increased in BN/AMA+ (6.59% and 2.36%) and decreased in PBC (− 4.89%/year and − 3.88%/year). In BN/AMA+ individuals there was positive correlation of ELF with IIF-AMA titer (r = 0.465; p < 0.001) and with anti-PDC-E2 levels (r = 0.239; p < 0.001). Expansion of autoantibody targets along time occurred in 39% BN/AMA+ and 49% PBC patients. The frequency of BN/AMA+ with high probability of having established PBC increased from 7 to 14%. Conclusions BN/AMA+ individuals present an orchestrated increase in ELF score and humoral autoimmune response over time, indicating an opportunity for early therapeutic intervention and prevention in autoimmunity.

Accuracy of liver stiffness measurement in assessing liver fibrosis in naive patients with primary biliary cholangitis

2020 ◽  
Vol 73 ◽  
pp. S478-S479
Author(s):  
Laura Cristoferi ◽  
Alessandra Nardi ◽  
Mauro Viganò ◽  
Cristina Rigamonti ◽  
Elisabetta Degasperi ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Liver Stiffness ◽  
Primary Biliary Cholangitis ◽  
Liver Stiffness Measurement ◽  
Stiffness Measurement

Relationship of cyclic AMP to secretin stimulation of the pancreas

1973 ◽  
Vol 14 (2) ◽  
pp. 172-176 ◽  
Author(s):  
Ronald K. Tompkins ◽  
Stephen L. Kuchenbecker
Keyword(s):  
Cyclic Amp ◽  
Secretin Stimulation ◽  
Relationship Of ◽  
Stimulation Of
Sign in / Sign up

Export Citation Format

Share Document